AI filing briefs · archive

8-K filings in April 2026, explained

1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

1 of 1,298 briefs matches

newest first · times in ET

BIIBBIOGEN INC. Apr 6, 6:31 AM ET

Biogen expects $34 million Q1 2026 R&D charge, cutting EPS by $0.19 per share

Negative earnings Written later 2.02

Biogen said its first-quarter 2026 GAAP and non-GAAP results will include about $34 million in pre-tax acquired in-process research and development, upfront and milestone expense. The company said the charge will reduce net income per diluted share by about $0.19. Quarter results are not final and may differ from these preliminary estimates.

Expected pre-tax charge of approximately $34 million for acquired in-process R&D, upfront and milestone expense in Q1 2026
Estimated impact of approximately $0.19 per diluted share on both GAAP and non-GAAP net income
Quarter ended March 31, 2026 results have not been finalized and remain subject to closing procedures

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.